Refreshing Medicine, Today
Exopharm is a clinical-stage biopharmaceutical company using exosomes to generate a new class of cell-free medicines. Our mission is to be the global leader in exosome-based therapeutics.
Clinical-scale manufacturing of Extracellular Vesicles (EVs)
Exopharm’s LEAP Technology provides a key step in the manufacturing process to isolate and purify EVs, including exosomes, from a variety of cell sources. LEAP provides Exopharm unparalleled access to high-purity EVs, allowing it to solve other manufacturing and characterization challenges and to bring an EV-based medicine into human clinical trials for the first time.
Leaders in the development of EV-based medicines
Exopharm is developing and commercialising EVs as therapeutics, initially with our naïve EV products, Plexaris™ and Cevaris™, and ultimately with engineered EVs including Fortrexo™.
LEAP Technology has provided Exopharm access to large quantities of pure and consistent EVs, enabling rapid progress in EV characterisation and standardisation, and therapeutic application of EVs. Partner with Exopharm to jointly push the boundaries in regenerative medicine and to expedite the development of exosome-based therapies for patients.
Visit our Resources section for investor information, company updates, and our news and media section.
An experienced and dedicated team
Founded in 2013 by Dr Ian Dixon on the LEAP Technology, Exopharm has built a highly skilled team with broad manufacturing, scientific and commercial expertise. Our success would not be possible without the exceptional minds working together behind the scenes with a range of capabilities across specialised areas.